Do insulinotropic glucose-lowering drugs do more harm than good? the hypersecretion hypothesis revisited

Diabetologia

Volumn 53, Issue 10, 2010, Pages 2105-2111

  Rustenbeck, I ^b   Baltrusch, S ^a   Tiedge, M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b NONE

Author keywords

Antidiabetic drugs; Beta cell; Glucose lowering drugs; Hyperinsulinaemia; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIAZOXIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; IMIDAZOLINE DERIVATIVE; INSULIN; METFORMIN; ROSIGLITAZONE; TOLBUTAMIDE;

DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GENETIC RISK; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS;

EID: 77958024206     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1839-0     Document Type: Review

References (50)

1. Pfeiffer EF, Schoffling K, Steigerwald H, Treser G, Otto M (1957) Problem of secondary failure in the oral treatment of diabetes mellitus. Dtsch Med Wochenschr 82:1528-1531 (article in German)
2. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D (1986) Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diab Care 9:129-133
3. U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258
4. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012
5. van Haeften TW (2002) Early disturbances in insulin secretion in the development of type 2 diabetes mellitus. Mol Cell Endocrinol 197:197-204
6. Aston-Mourney K, Proietto J, Morahan G, Andrikopoulos S (2008) Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia 51:540-545
7. Glaser B, Kesavan P, Heyman M et al (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338:226-230
8. Osbak KK, Colclough K, Saint-Martin C et al (2009) Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30:1512-1526
9. Lortz S, Gurgul-Convey E, Lenzen S, Tiedge M (2005) Importance of mitochondrial superoxide dismutase expression in insulin-producing cells for the toxicity of reactive oxygen species and proinflammatory cytokines. Diabetologia 48:1541-1548
10. Eizirik DL, Cardozo AK, Cnop M (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29:42-61
11. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
12. Grill V, Bjorklund A (2001) Overstimulation and beta-cell function. Diabetes 50(Suppl 1):S122-S124
13. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
14. Reaven GM (2005) Insulin resistance, the insulin resistance syndrome, andcardiovasculardisease. PanminervaMed47:201-210
15. Stadler M, Pacini G, Petrie J, Luger A, Anderwald C (2009) Beta cell (dys)function in non-diabetic offspring of diabetic patients. Diabetologia 52:2435-2444
16. Perry JR, Frayling TM (2008) New gene variants alter type 2 diabetes risk predominantly through reduced beta-cell function. Curr Opin Clin Nutr Metab Care 11:371-377
17. Ferrannini E (2007) Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 92:396-398
18. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802-1812
19. Poitout V, Robertson RP (2002) Minireview: secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339-342
20. Rustenbeck I (2002) Desensitization of insulin secretion. Biochem Pharmacol 63:1921-1935
21. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110
22. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10(Suppl 4):32-42
23. Marchetti P, Bugliani M, Lupi R et al (2007) The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 50:2486-2494
24. Davis SN, Granner DK (1996) Insulin, oral hypoglycaemic agents and the pharmacology of the endocrine pancreas. In: Hardman JG, Goodman Gilman A, Limbird LE (eds) The pharmacological basis of therapeutics. McGraw-Hill, New York, pp 1487-1517
25. Feldman JM, Lebovitz HE (1969) Appraisal of the extrapancreatic actions of sulfonylureas. Arch Intern Med 123:314-322
26. Shapiro ET, van Cauter E, Tillil H et al (1989) Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69:571-576
27. Panten U, Zünkler BJ, Scheit S, Kirchhoff K, Lenzen S (1986) Regulation of energy metabolism in pancreatic islets by glucose and tolbutamide. Diabetologia 29:648-654
28. Henquin JC (1998) A minimum of fuel is necessary for tolbutamide to mimic the effects of glucose on electrical activity in pancreatic beta-cells. Endocrinology 139:993-998
29. Birkeland KI, Furuseth K, Melander A, Mowinckel P, Vaaler S (1994) Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. Diab Care 17:45-49
30. Schauder P, Arends J, Frerichs H (1977) Onset and reversibility of changes in secretory function and composition of isolated rat pancreatic islets following long-term administrationof high or low tolbutamide doses. Metabolism 26:9-15
31. Efanova IB, Zaitsev SV, Zhivotovsky B et al (1998) Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 273:33501-33507
32. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501-506
33. Remedi MS, Nichols CG (2008) Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med 5:e206
34. Rustenbeck I, Krautheim A, Jörns A, Steinfelder HJ (2004) Beta- cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues. Biochem Pharmacol 67:1733-1741
35. Hellman B (1965) Studies in obese-hyperglycemic mice. Ann NY Acad Sci 131:541-558
36. Radtke M, Kollind M, Qvigstad E, Grill V (2007) Twelve weeks' treatment with diazoxide without insulin supplementation in type 2 diabetes is feasible but does not improve insulin secretion. Diabet Med 24:172-177
37. Grill V, Radtke M, Qvigstad E, Kollind M, Bjorklund A (2009) Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences. Diabetes Obes Metab 11(Suppl 4):143-148
38. Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177
39. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagonlike peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
40. Doyle ME, Egan JM (2007) Mechanisms of action of glucagonlike peptide 1 in the pancreas. Pharmacol Ther 113:546-593
41. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399-416
42. Grimsby J, Matschinsky FM, Grippo JF (2004) Discovery and action of glucokinase activators. In: Matschinsky FM, Magnuson MA (eds) Glucokinase and glycemic disease: from basics to novel therapeutics. Karger, Basel, pp 360-378
43. Morgan NG, Chan SL (2001) Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharm Des 7:1413-1431
44. Proks P, Ashcroft FM (1997) Phentolamine block of KATP channels is mediated by Kir6.2. Proc Natl Acad Sci USA 94:11716-11720
45. Efendic S, Efanov AM, Berggren PO, Zaitsev SV (2002) Two generations of insulinotropic imidazoline compounds. Diabetes 51 (Suppl 3):S448-S454
46. Hatlapatka K, Wienbergen A, Kuhne C, Jörns A, Willenborg M, Rustenbeck I (2009) Selective enhancement of nutrient-induced insulin secretion by ATP-sensitive K +channel-blocking imidazolines. J Pharmacol Exp Ther 331:1033-1041
47. Papaccio G, Graziano A, Valiante S, D'Aquino R, Travali S, Nicoletti F (2005) Interleukin (IL)-1beta toxicity to islet beta cells: efaroxan exerts a complete protection. J Cell Physiol 203:94-102
48. Ferrannini E, Mingrone G (2009) Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diab Care 32:514-520
49. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
50. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589